Integral Derivatives’s Ionis Pharmaceuticals IONS Stock Holding History

Integral Derivatives’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-12,700	Closed	-$639K	–	834
2017 Q4	$639K	Sell	12,700 -400	-3%	-$21.9K	0.01%	642
2017 Q3	$664K	Sell	13,100 -4,000	-23%	-$210K	0.01%	633
2017 Q2	$870K	Buy	17,100 +1,100	+7%	+$51.2K	0.02%	525
2017 Q1	$643K	Buy	16,000 +700	+5%	+$31.4K	0.01%	664
2016 Q4	$732K	Buy	15,300 +7,700	+101%	+$305K	0.01%	603
2016 Q3	$278K	Buy	+7,600	New	+$238K	0.01%	804
2016 Q2	–	Sell	-6,200	Closed	-$251K	–	1019
2016 Q1	$251K	Hold	6,200	–	–	0.01%	689
2015 Q4	$384K	Buy	+6,200	New	+$335K	0.01%	723
2015 Q3	–	Sell	-5,300	Closed	-$305K	–	1179
2015 Q2	$305K	Buy	+5,300	New	+$337K	0.01%	865

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Integral Derivatives's IONS Position: Q1 2016 in Review

Integral Derivatives sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 33,847 shares — an estimated $1.37M sold.

Integral Derivatives first reported a position in IONS in Q2 2014 and held it in 7 quarters. The position peaked at $2.75M in Q4 2014. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

Integral Derivatives reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Integral Derivatives sold 33,847 Ionis Pharmaceuticals shares in Q1 2016, an estimated $1.37M.
Integral Derivatives first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 7 quarters.
Integral Derivatives's Ionis Pharmaceuticals position peaked at $2.75M in Q4 2014.
314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Integral Derivatives's 13F filing for Q1 2016, filed 12 Apr 2016.